MTOR and prostate carcinoma: Specifically, we propose that CAMKK2 enables metabolic syndrome, which causes increased levels of circulating insulin or some insulin-like molecule that can promote oncogenic mTOR signaling in distant prostate cancer cells (Figure 7).